tradingkey.logo
搜尋

Codexis Inc

CDXS
添加自選
2.470USD
+0.080+3.35%
收盤 07/02, 13:00美東報價延遲15分鐘
222.99M總市值
虧損本益比TTM

Codexis Inc

2.470
+0.080+3.35%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.35%

5天

+3.35%

1月

-11.79%

6月

+53.42%

今年開始到現在

+51.53%

1年

-10.83%

關鍵數據
2.400今開
2.500最高
1.36M成交量
虧損本益比TTM
虧損本益比動
--股利TTM
1.50%換手率
2.390昨收
2.400最低
2.89M成交額
虧損本益比靜
5.79市淨率
0.00%股息率 TTM
-24.77%ROA
3.87052週最高
1.82量比
-65.28M淨利潤
90.28M總股本
-0.3495每股盈餘TTM
2.50Beta
-68.90%ROE
0.95852週最低
4.18%振幅
86.46%毛利率
222.99M總市值
-3.23回報/風險
4.54%風險率

TradingKey Codexis Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Codexis Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名78/387位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為6.58。中期看,股價處於上升通道。近一個月,市場表現較差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Codexis Inc評分

相關信息

行業排名
78 / 387
全市場排名
179 / 4565
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Codexis Inc亮點

亮點風險
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
業績增長期
公司處於發展階段,最新年度總收入70.39M美元
估值低估
公司最新PE估值-7.07,處於3年歷史低位
機構減倉
最新機構持股66.34M股,環比減少17.31%
ETHSX持倉
明星投資者ETHSX持倉,最新持倉210.50K股

分析師目標

基於 7 分析師
買入
評級
6.583
目標均價
+175.45%
漲幅空間

Codexis Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Codexis Inc簡介

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
公司代碼CDXS
公司Codexis Inc
CEOMoore (Alison)
網址https://www.codexis.com/

常見問題

Codexis Inc(CDXS)的當前股價是多少?

Codexis Inc(CDXS)的當前股價是 2.47。

Codexis Inc 的股票代碼是什麼?

Codexis Inc的股票代碼是CDXS。

Codexis Inc股票的52週最高點是多少?

Codexis Inc股票的52週最高點是3.87。

Codexis Inc股票的52週最低點是多少?

Codexis Inc股票的52週最低點是0.96。

Codexis Inc的市值是多少?

Codexis Inc的市值是224.51M。

現在Codexis Inc(CDXS)的股票是買入、持有還是賣出?

根據分析師評級,Codexis Inc(CDXS)的總體評級為買入,目標價格為6.58。

Codexis Inc(CDXS)股票的每股收益(EPS TTM)是多少

Codexis Inc(CDXS)股票的每股收益(EPS TTM)是-0.50。